CytRx soars as aldoxorubicin doubles PFS in sarcoma
This article was originally published in Scrip
Executive Summary
CytRx's stock price closed 68.2% higher at $4.02 per share on 11 December after the Los Angeles-based company revealed a statistically significant doubling of progression-free survival (PFS) in a Phase IIb clinical trial for aldoxorubicin in the treatment of advanced soft tissue sarcomas. The company's market cap is now $168.7m.